These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 8498963)

  • 1. The renin-angiotensin paradigm. Practical therapeutical consequences of basic research.
    Ganten D
    Arzneimittelforschung; 1993 Feb; 43(2A):191-7. PubMed ID: 8498963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The transition from experimental to clinical pharmacology: the renin-angiotensin paradigm.
    Ganten D
    J Cardiovasc Pharmacol; 1993; 22 Suppl 1():S14-29. PubMed ID: 7507536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Oral inhibitors of renin and their potential use as therapeutic agents in treating hypertension].
    Abassi Z; Armaly Z; Nakhoul F; Hoffman A
    Harefuah; 2008 Jun; 147(6):536-42, 573. PubMed ID: 18693632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Frontier of mycobacterium research--host vs. mycobacterium].
    Okada M; Shirakawa T
    Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma renin activity and angiotensin I and aldosterone concentrations in cats with hypertension associated with chronic renal disease.
    Jensen J; Henik RA; Brownfield M; Armstrong J
    Am J Vet Res; 1997 May; 58(5):535-40. PubMed ID: 9140564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transgenic rats: tools to study the function of the renin-angiotensin system.
    Bader M; Ganten D
    Clin Exp Pharmacol Physiol Suppl; 1996; 3():S81-7. PubMed ID: 8993844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular genetics of the renin-angiotensin-aldosterone system in human hypertension.
    Corvol P; Soubrier F; Jeunemaitre X
    Pathol Biol (Paris); 1997 Mar; 45(3):229-39. PubMed ID: 9296068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Molecular genetics methods in the study of hereditary essential hypertension].
    Jindra A; Horký K
    Cas Lek Cesk; 1998 Jan; 137(2):39-43. PubMed ID: 9511264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Selected components of the kallikrein-kinin system and of the renin-angiotensin-aldosterone system in offspring of parents with hypertension].
    Marzecka J
    Ann Acad Med Stetin; 1996; 42():123-38. PubMed ID: 9199117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antihypertensive strategy based on angiotensin II receptor blockers: a new gateway to reduce risk in hypertension.
    Tocci G; Sciarretta S; Facciolo C; Volpe M
    Expert Rev Cardiovasc Ther; 2007 Jul; 5(4):767-76. PubMed ID: 17605654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker therapy to reduce cardiovascular events in high-risk patients: part 2.
    Bommer WJ
    Prev Cardiol; 2008; 11(4):215-22. PubMed ID: 19476574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New treatment guidelines for a patient with diabetes and hypertension.
    Mogensen CE
    J Hypertens Suppl; 2003 Mar; 21(1):S25-30. PubMed ID: 12769164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting mechanisms of hypertensive vascular disease with dual calcium channel and renin-angiotensin system blockade.
    Weir MR
    J Hum Hypertens; 2007 Oct; 21(10):770-9. PubMed ID: 17597800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Does the rennin inhibitor aliskiren offer promising novel opportunities in the treatment of cardiovascular diseases?].
    Horký K
    Vnitr Lek; 2007 Apr; 53(4):364-70. PubMed ID: 17578167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renin-angiotensin system gene polymorphisms influence blood pressure and the response to angiotensin converting enzyme inhibition.
    Hingorani AD; Jia H; Stevens PA; Hopper R; Dickerson JE; Brown MJ
    J Hypertens; 1995 Dec; 13(12 Pt 2):1602-9. PubMed ID: 8903618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenetics of antihypertensive treatment.
    Arnett DK; Claas SA; Glasser SP
    Vascul Pharmacol; 2006 Feb; 44(2):107-18. PubMed ID: 16356784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypertension mega-trials with cardiovascular end points: effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
    Kjeldsen SE; Julius S
    Am Heart J; 2004 Nov; 148(5):747-54. PubMed ID: 15523303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pathophysiological and clinical implications of AT(1) and AT(2) angiotensin II receptors in essential hypertension].
    Burnier M
    Drugs; 2002; 62 Spec No 1():21-9. PubMed ID: 12036386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Role of renin angiotensin system in the vasopressor mechanisms of hypertension--gene analyses and tissue renin angiotensin system].
    Nishimura M; Yoshimura M
    Rinsho Byori; 1995 Nov; 43(11):1128-32. PubMed ID: 8551676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.